Compare CCK & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCK | DVA |
|---|---|---|
| Founded | 1906 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.0B |
| IPO Year | 2003 | 2002 |
| Metric | CCK | DVA |
|---|---|---|
| Price | $107.19 | $149.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $122.75 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 873.5K | 724.0K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 79.72 | N/A |
| EPS | 6.38 | ★ 9.84 |
| Revenue | $11,665,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $4.97 | $3.85 |
| Revenue Next Year | $2.39 | $3.07 |
| P/E Ratio | $16.92 | ★ $15.32 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $83.23 | $101.00 |
| 52 Week High | $116.62 | $159.42 |
| Indicator | CCK | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 50.72 |
| Support Level | $98.41 | $146.05 |
| Resistance Level | $107.71 | $152.31 |
| Average True Range (ATR) | 2.70 | 3.54 |
| MACD | 0.98 | -0.85 |
| Stochastic Oscillator | 83.05 | 42.07 |
Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.